文献速递脊柱关节炎其他结缔组织病

生物制剂类别与治疗线对银屑病患者银屑病关节炎风险的影响:一项基于人群的队列研究

Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study.
PubMed 文献 · RMD Open · 2026-05-07

该研究纳入2002至2022年间2819例因银屑病起始生物制剂治疗的患者,评估不同生物制剂对银屑病关节炎发生风险的影响。一线治疗中,抗IL-23p19药物较TNF抑制剂显著降低PsA风险(HR 0.13;95%CI 0.02-0.96;p=0.045);二线治疗中仅IL-17抑制剂较TNF抑制剂显著降低PsA风险(HR 0.37;95%CI 0.16-0.85;p=0.019)。

要点

  • 一线抗IL-23p19药物较TNF抑制剂与更低的PsA发生风险相关(HR 0.13;95%CI 0.02-0.96;p=0.045)
  • 二线IL-17抑制剂较TNF抑制剂与更低的PsA风险独立相关(HR 0.37;95%CI 0.16-0.85;p=0.019)
  • 二线抗IL-12/23(HR 0.14;95%CI 0.02-1.05;p=0.056)和抗IL-23p19(HR 0.46;95%CI 0.20-1.07;p=0.070)仅呈趋势

核心结论

  • 在银屑病患者中,一线抗IL-23p19药物较TNF抑制剂与更低的PsA发生风险相关,二线治疗中仅IL-17抑制剂较TNF抑制剂与PsA风险显著降低独立相关。

研究设计与样本

  • 基于人群的队列研究,纳入2002至2022年间因银屑病起始生物制剂治疗的2819例患者,包含TNF抑制剂、IL-17抑制剂、IL-23p19抑制剂和IL-12/23抑制剂,主要结局为新发PsA。

主要发现

  • 2819例一线生物制剂治疗患者中400例(14.2%)发生PsA;1246例二线生物制剂治疗患者中125例(10.0%)发生PsA。
  • 多变量Cox回归中,一线抗IL-23p19药物较TNF抑制剂与更低的PsA风险显著相关(HR 0.13;95%CI 0.02至0.96;p=0.045)。
  • 二线治疗中,IL-17抑制剂较TNF抑制剂与PsA风险显著降低独立相关(HR 0.37;95%CI 0.16至0.85;p=0.019),抗IL-12/23(HR 0.14;95%CI 0.02至1.05;p=0.056)和抗IL-23p19(HR 0.46;95%CI 0.20至1.07;p=0.070)仅呈趋势。

临床怎么用

  • 在银屑病生物制剂选择时,可结合治疗线次关注不同类别药物对PsA发生风险的影响,一线抗IL-23p19及二线IL-17抑制剂较TNF抑制剂与更低的PsA风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence suggests that biologic therapies may differentially influence the development of PsA; however, there are no data on the relative ability of second-line biological therapy to prevent PsA. AIM: To evaluate the impact of biologic therapy on the risk of incident PsA in patients with PsO with a focus on second-line biologic therapy. METHODS: We identified 2819 patients who initiated biologic therapy for PsO between 2002 and 2022, including Tumor Necrosis Factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-23p19 inhibitors and IL-12/23 inhibitors. The primary outcome was incident PsA. Kaplan-Meier survival analysis and Cox proportional hazards models were used to evaluate arthritis-free survival and HRs for the development of PsA. Risk was assessed separately for first-line and second-line biologic therapy. RESULTS: Among 2819 patients with PsO initiating first-line biologic therapy, 400 (14.2%) developed PsA. In multivariable Cox regression, first-line anti-IL-23p19 agents were significantly associated with a lower risk of developing PsA compared with TNF inhibitors (HR 0.13; 95% CI 0.02 to 0.96; p=0.045). Among 1246 patients receiving second-line biologics, 125 (10.0%) developed PsA. Notably, in second-line therapy, only IL-17 inhibitors were independently associated with a statistically significant reduction in PsA risk versus TNF inhibitors (HR 0.37; 95% CI 0.16 to 0.85; p=0.019), with trends observed for anti-IL-12/23 (HR 0.14; 95% CI 0.02 to 1.05; p=0.056) and anti-IL-23p19 (HR 0.46; 95% CI 0.20 to 1.07; p=0.070). CONCLUSIONS: This is the first study to evaluate second-line biological therapy in relation to PsA risk. IL-17 inhibitor therapy was significantly associated with a reduced risk of incident PsA compared with TNF inhibitors.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Watad A, Elizur Y, Hen O, et al. Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study. RMD Open. 2026. PMID: 42097693. doi:10.1136/rmdopen-2025-006687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。